JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas
Abstract
Aims: The This study was to determine the clinicopathological findings of patients with primary central nervous system lymphoma (PCNSL) as real-life data, examine their treatment approaches, and define the prognostic factors.
Methods: Eighty-four patients who presented with a diagnosis of PCNSL between January 2008 and July 2021 were included in this study. The treatments received by the patients and their survival outcomes were retrospectively analyzed.
Results: The median age at diagnosis was 55 (18-80 years). The median progression-free survival (PFS) was 16.8 months (12.4-21.2 months), while the median overall survival (OS) was 18 months (13.7-22.4 months) in all patients. The most commonly used chemotherapy was high-dose methotrexate based regimens, which were preferred in 68 (81%) patients. Objective response rate and disease control rate were 75% and 83.3%, respectively. Consolidation therapy was an independent prognostic factor for PFS (HR:0.32, 95% CI, 0.18-0.55, p<0.001). Patients who received consolidation therapy were observed to have a 67% reduction in mortality compared to those who did not (HR:0.33, 95% CI, 0.19-0.57, p<0.001). Also, high risk in Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model was found to be associated with a 2-fold increase in mortality compared to the good risk group (HR:2.04, 95% CI, 1.02-3.56, p=0.022). Toxicity of any grade was observed in 78 (92.9%) patients. There were 3 (3.6%) patients who died due to treatment toxicity.
Conclusion: Consolidation therapy was found to be an independent predictive factor for both OS and PFS in PCNSL. In addition, high risk class according to MSKCC prognostic model was found to be associated with increased mortality.

Keywords : Primary central nervous system lymphoma, treatment, chemotherapy, radiotherapy, prognosis

Download Article


1. Schaff LR, Grommes C. Primary central nervous system lymphoma.Blood. 2022;140(9):971-979. doi:10.1182/blood.2020008377
2. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414-1418. doi:10.1038/bjc.2011.357
3. Paydas S. Primary central nervous system lymphoma: essential points in diagnosis and management. Med Oncol. 2017;34(4):61. doi:10.1007/s12032-017-0920-7
4. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92(2):261-266. doi:10. 3171/jns.2000.92.2.0261
5. Chojak R, Kozba-Gosztyla M, Polanska K, et al. Surgical resection versus biopsy in the treatment of primary central nervous system lymphoma: a systematic review and meta-analysis. J Neurooncol. 2022; 160(3):753-761. doi:10.1007/s11060-022-04200-7
6. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.J Clin Oncol. 2006;24(36):5711-5715. doi:10.1200/JCO.2006.08.2941
7. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.J Clin Oncol. 2005;23(22):5034-5043. doi:10. 1200/JCO.2005.13.524
8. Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.Neuro Oncol. 2018;20(5):687-694. doi:10.1093/neuonc/nox187
9. Yuan XG, Huang YR, Yu T, et al. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.Ann Hematol. 2020;99(1):93-104. doi:10.1007/s00277-019-03821-9
10. Sarpel SC, Paydas S, Tuncer I, Varinli S, Koksal M, Akoglu T. Non-Hodgkin&rsquo;s lymphomas in Turkey. Cancer. 1988;62(8):1653-1657. doi:10. 1002/1097-0142(19881015)62:8&lt;1653::aid-cncr2820620833&gt;3.0.co;2-0
11. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.Lancet Haematol. 2017;4(11):e510-e523. doi:10. 1016/S2352-3026(17)30174-6
12. Prica A, Chan K, Cheung MC. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a decision analysis.Br J Haematol. 2012; 158(5):600-607. doi:10.1111/j.1365-2141.2012.09208.x
13. Schlegel U. Primary CNS lymphoma.Ther Adv Neurol Disord. 2009; 2(2):93-104. doi:10.1177/1756285608101222
14. Weller M, Martus P, Roth P, Thiel E, Korfel A; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm.Neuro Oncol. 2012;14(12):1481-1484. doi:10.1093/neuonc/nos159
15. Wu S, Wang J, Liu W, et al. The role of surgical resection in primary central nervous system lymphoma: a single-center retrospective analysis of 70 patients.BMC Neurol. 2021;21(1):190. doi:10.1186/s12883-021-02227-3
16. Zhang Q, Wang DW, Shu HS. Outcome of primary central nervous system lymphoma treated with combined surgical resection and high- dose methotrexate chemotherapy: a single-institution retrospective study. Turk Neurosurg. 2022;32(1):1-5. doi:10.5137/1019-5149.JTN. 24054-19.2
17. Jahr G, Da Broi M, Holte H Jr, Beiske K, Meling TR. The role of surgery in intracranial PCNSL.Neurosurg Rev. 2018;41(4):1037-1044. doi:10. 1007/s10143-018-0946-0
18. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.Lancet. 2009;374(9700):1512-1520. doi:10.1016/S0140-6736(09)61416-1
19. Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.Neurology. 2014;83(3):235-239. doi:10.1212/WNL. 0000000000000593
20. Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).J Clin Oncol. 2013;31(25): 3061-3068. doi:10.1200/JCO.2012.46.9957
21. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin&rsquo;s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315.Int J Radiat Oncol Biol Phys. 1992;23(1):9-17. doi: 10.1016/0360-3016(92)90538-s
22. Shibamoto Y, Ogino H, Hasegawa M, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005;62(3):809-813. doi:10.1016/j.ijrobp.2004.12.043
23. Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma.Chin Clin Oncol. 2015;4(1):11. doi: 10.3978/j.issn.2304-3865.2015.02.01
24. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-1047. doi:10.1016/S1470-2045(10)70229-1
25. Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388-e397. doi:10.1016/S2352-3026(16)30050-3
26. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403-1410. doi:10.1182/blood-2014-10-604561
27. Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary cns lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823-833. doi:10.1200/JCO.18.00306
28. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.J Clin Oncol. 2003;21(2):266-272. doi:10.1200/JCO. 2003.09.139
29. Jang JE, Kim YR, Kim SJ, et al. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. Eur J Cancer. 2016;57:127-135. doi:10.1016/j.ejca.2016.01.016
30. Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).Leukemia. 2017;31(4):846-852. doi:10.1038/leu.2016.334
Article available in :
Volume 3, Issue 3, 2025
Page : 49-56
https://doi.org/10.51271/JCHOR-0062
Article Information
Received : 02 Şub 2025
Accepted : 28 Şub 2025
Published : 08 Ağu 2025
Corresponding Author :

Senar Ebinç: Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkiye

[email protected]
Citation : Akdeniz N, Ebinç S, Barışta İ, et al. Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas. J Curr Hematol Oncol Res. 2025;3(3):49-56.

Read: 230
Download : 357
Cited: 0
_Footer